statnews.com·May 19, 2026
Relay Therapeutics announced promising Phase 2 data for its drug zovegalisib, resulting in a 9% increase in its shares, while Eli Lilly achieved a notable milestone by ranking first in both innovation and invention categories in a report analyzing drugmakers' R&D performance.
Relay Therapeutics' promising Phase 2 data for their drug zovegalisib in treating rare vasculature development diseases has significantly boosted their stock, signaling a potential investment opportunity. Additionally, Eli Lilly's top ranking in both innovation and invention for R&D performance highlights their strong position in the sector, suggesting they are a key player to watch for future developments in drug discovery and development.